Published by
Benzinga
Benzinga
Two new drugs, Orforglipron and Retatrutide, are set to redefine the obesity treatment landscape with their potential affordability and unprecedented efficacy, Scientific American reports. Potential Game Changers: Orforglipron, one of the two drugs, is anticipated to be easier to use, produce, and likely cheaper than existing treatments. Internal-medicine physician Sean Wharton at McMaster University, who co-authored the orforglipron study, says “I see it as a game changer, myself.” The second drug, Retatrutide offers an unprecedented level of efficacy and can potentially raise the bar for tre…